Plant-based oil for critical care patients

A study has highlighted the benefits of Vegaven, a novel plant-based lipid emulsion developed from Ahiflower oil (refined Buglossoides arvensis seed oil), as an alternative to traditional fish oil-based emulsions in parenteral nutrition (PN). According to Natures Crops International, PN is critical for patients who cannot eat orally due to compromised digestive function, such as pre-term infants, critically ill patients, and chemotherapy patients.

In the study, which conducted on neonatal piglets, Vegaven outperformed SMOFlipid (a fish oil-based emulsion) by:

  • Protecting the liver and providing more abundant anti-inflammatory omega-3 derivatives.
  • Maintaining critical omega-3 DHA and omega-6 ARA levels in the brain, despite containing neither directly.
  • Enhancing insulin signaling for better glucose control.
  • Mitigating the effects of a "leaky gut" by reducing inflammation in the liver, pancreas, and brain.

Commenting in an editorial in The Journal of Nutrition, lipid researcher Prof. Philip Calder stated, “In general, this new study shows superiority of the Ahiflower oi-lbased emulsion over the fish oil containing emulsion...the findings suggest anti-inflammatory, immune supporting, insulin sensitizing and hepatoprotective effects of theAhiflower oil emulsion relative to the comparator(s). These effects are all clinically relevant.” Referencing prrevious findings, Prof Calder noted: “The findings of the two studies indicate superiority of the Ahiflower oil blendover pure soybean oil, pure fish oil and an oil blend that includes fish oil in these preclinical models. The superiority of the Ahiflower oil based emulsion over those containing fish oil is quite remarkable and requires explanation.” 

Beyond PN applications, Ahiflower oil is recognized for its sustainability and versatility as a plant-based omega-3 source with GRAS status and other regulatory clearances. It is currently available in supplements for consumers seeking balanced omega-3 intake with anti-inflammatory and gut health benefits. Researchers are progressing toward clinical approval of Vegaven to enhance patient outcomes in critical care settings.

Ashwagandha extract for anxiety

Arjuna Natural Pvt. Ltd. shared a new clinical study showcasing the efficacy of its proprietary Shoden brand ashwagandha extract in alleviating stress and anxiety, even at low doses. Published in Heliyon, the randomized, double-blind, placebo-controlled trial with 60 participants experiencing high stress and anxiety levels tested Shoden at 60mg and 120mg daily doses for 60 days.

Key findings:

  • Anxiety reduction: 59% improvement (HAMA scale) vs. placebo.
  • Cortisol reduction: 66%-67% drop in morning cortisol levels among Shoden groups, compared to 2.2% in placebo.
  • Testosterone boost: Significant increases observed in men.
  • Stress perception and overall functioning: Marked improvements in PSS, CGI, and PGIC scores.
  • Low-Dose Effectiveness: Benefits achieved at doses as low as 60mg daily, a breakthrough for formulators seeking efficient and low-cost solutions.

Shoden, standardized to 35% withanolide glycosides, modulates the hypothalamic-pituitary-adrenal (HPA) axis, reducing cortisol and enhancing neurotransmitter activity (serotonin, acetylcholine, GABA), the company says. These mechanisms address prolonged stress while supporting mental and physical well-being.

Shoden is derived from select ashwagandha roots and leaves using sustainable practices that support farmers and maintain soil health. It is backed by 11 studies, 23 patents, and extensive safety evaluations, including animal toxicity studies.

Bioavailability of folate ingredient

A new study in the International Journal of Applied Pharmaceutics evaluated the pharmacokinetic profile of HY-FOLIC, a finished product produced by PT. Simex Pharmaceutical Indonesia, versus folic acid after single oral administration in healthy volunteers. In partnership with Gnosis by Lesaffre, the new randomized, open-label, study showed key advantages of active folate including:

  • Superior Absorption and Bioavailability: HY-FOLIC (Quatrefolic) is two-fold more bioavailable than folic acid (higher peak plasma concentration Cmax and AUCt), ensuring the body can access and utilize folate twice as effectively.
  • HY-FOLIC, which delivers (6S)-5-Methyltetrahydrofolic Acid, Glucosamine Salt as Quatrefolic active folate, is twice more bioavailable than folic acid.
  • Avoidance of Metabolic Limitations: Unlike folic acid, HY-FOLIC bypasses the metabolic conversion steps requiring the DHFR and MTHFR enzymes, making it particularly beneficial for individuals with genetic polymorphisms (~40% of the worldwide population) that impair folic acid metabolism.
  • Reduction in Unmetabolized Folic Acid (UMFA): HY-FOLIC resulted in significantly lower levels of UMFA, which can accumulate in the bloodstream when folic acid is not fully metabolized, potentially causing adverse effects.
  • Clinical Importance in Specific Populations: This study highlights HY-FOLIC as an ideal supplement for groups with higher folate demands, such as pregnant women, individuals with folate deficiencies/inadequacies, or those undergoing methotrexate therapy, where optimal folate availability is crucial.

Folate (vitamin B9) plays a key role in DNA synthesis, cell division, and proper neurological development of the fetus. While folic acid is the current recommendation for individuals looking to become pregnant, many women have an MTHFR polymorphism, which inhibits and reduces the conversion of folic acid into its active form, 5-MTHF; potentially affecting folate bioavailability. Quatrefolic offers a more effective solution for this genetic mutation as it does not require conversion in the body. “We have espoused the need for the standard of care to change...We contend that clinically validated Quatrefolic offers substantial advantages over folic acid, but also for a wider population. This study provides another strong element to that argument,” shared Jean Francois Jeanne, Substantiation and Application Manager at Gnosis by Lesaffre.

Natural bioactive molecules to reduce cold symptoms

Peer-reviewed research published in PLOS ONE highlights the effectiveness of Biovanta's immune-supporting bioactive formulation in reducing common cold symptoms. The multi-center, placebo-controlled clinical trial, titled Supporting Respiratory Epithelia and Lowering Inflammation to Effectively Treat Common Cold Symptoms, involved 157 participants across six U.S. cities. The trial tested the efficacy of a throat spray containing an immune complex of bioactive ingredients, including lactoferrin for immune-modulating properties, lysozyme and salicylates for anti-inflammatory effects, and aloe for soothing and immune-supporting benefits. Applied Biological Laboratories, makers of the Biovanta brand of cold products, says the line is made from 100% natural ingredients.

The study measured outcomes over two days, evaluating eight doses of Biovanta's throat spray against a placebo. Key findings:

Participants using the Biovanta throat spray experienced:

  • 80% improvement in sore throat.
  • 70% reduction in overall symptoms measured by the Modified Jackson Score, which tracks congestion, nasal discharge, sneezing, cough, sore throat, headache, and malaise.
“The study confirms that strengthening the respiratory lining and reducing inflammation may be used to effectively treat the common cold,” said Dr. Nazlie Latefi, one of the authors of the study and co-founder of Applied Biological Laboratories. “These results represent a major breakthrough in a category that has seen little innovation in decades.”
 
Ronald Primas, M.D., FACP Clinical Instructor of Medicine Mount Sinai Hospital, added, “Most over-the-counter cold remedies demonstrate minimal or no efficacy compared to placebos, and many haven’t been clinically tested at all.”
 

Bioactive compounds from aged black garlic

Advanced mass spectrometry analysis has confirmed the authenticity and bioactive levels of key compounds found in Pharmactive's Abg10+. The proprietary aged black garlic (ABG) extract is designed and science-backed to help promote cardiovascular health. “Our aged garlic extract is produced under controlled temperature, without burning, which prevents the formation of harmful substances such as acrylamide and furfurals. Our traditional approach to aging and advanced extraction methods enhances the bioactive compounds, resulting in a purer and more beneficial product,” shared Carlos Rodríguez, Communications Manager for Pharmactive. 

The new study, which addresses recent industry concerns over fraudulent and mislabeled natural supplements reaching consumers, was published on August 2024 in the scientific journal, Foods. Led by Ignacio Jiménez Amezcua, Ph.D., the research applied multiple analytical mass-spectral methodologies to generate “fingerprints” of Abg10+ compared to 24 other commercial aged garlic supplements. The results showed a comprehensive range of analytical "fingerprints" establishing the purity and natural status of the product, affirming the concentrated presence of its key bioactive compounds branded as Agedgarlides.

The primary compound included in Agedgarlides is S-allyl-L-cysteine (SAC), accompanied by other bioactives present, including S-1-propenyl-L-cysteine (S1PC) and S-allylmercaptocysteine (SAMC). Manufactured in Spain, the company uses its ActiveNature Technology proprietary process to optimize the extraction and preservation of 100% native SAC and other bioactive compounds from aged garlic through a distinctive aging technique and eco-friendly water-based extraction.

Synbiotic for heart health

Research published in The Journal of the American College of Cardiology: Basic to Translational Science reveals novel connections between the gut microbiome, inflammation, and heart disease. The research, conducted by APC Microbiome Ireland in collaboration with Tate & Lyle, highlights the potential of synbiotics to protect against diet-induced cardiac damage. The prebiotic component used in the study was Tate & Lyle’s PROMITOR Soluble Corn Fibre.

Key findings, as outlined in a press release:

  • The study established the “gut-heart axis,” showing how gut microbe imbalances and gut-derived inflammation contribute to heart damage.
  • A synbiotic intervention combining a single probiotic with PROMITOR Soluble Corn Fibre significantly reduced heart muscle damage caused by diet-induced cardiac disease.
  • The synbiotic demonstrated results comparable to leading cardiac drugs in addressing heart disease associated with obesity and high blood pressure.

“This is the first time that a bacteria residing only in the gut has successfully been used to treat heart disease associated with obesity and high blood pressure, and our synbiotic treatment equals some of the best available cardiac drugs in a human scale model,” said Prof. Noel Caplice, Principal Investigator at APC and Chair of Cardiovascular Sciences at University College Cork.

 Dr. Kavita Karnik, Global Head of Nutrition, Regulatory and Scientific Affairs at Tate & Lyle, added, "At Tate & Lyle, we are proud to support and partner in cutting-edge research that explores how our dietary fibres, when combined with probiotic strains, can be used to improve health outcomes. It is exciting to see the integral role played by PROMITOR Soluble Corn Fibre in this unique symbiotic combination. This work creates new opportunities to leverage our science and ingredients to have a positive impact on significant public health challenges such as obesity and associated cardiometabolic outcomes."

Omega-3s for heart health

An observational study published in Mayo Clinic Proceedings highlights the cardiovascular benefits of maintaining higher omega-3 fatty acid levels. Researchers analyzed data from nearly 272,000 adults in the UK Biobank

Key findings:

  • Omega-3s are strongly linked to reduced risk of heart failure and improved survival outcomes in those with heart failure.
  • Individuals in the top 20% of plasma omega-3 levels were 21% less likely to develop heart failure over a 13.7-year follow-up compared to those in the bottom 20%.
  • Among the 1,239 participants with  heart failure at baseline, those with the highest omega-3 levels were 50% less likely to die from any cause during the follow-up period compared to those with the lowest levels.

In a press release, OmegaQuant noted that while this study was observational and not a randomized controlled trial (RCT), it aligns with extensive evidence from previous RCTs. Meta-analyses of RCTs involving:

  • 150,000 participants showed that omega-3s reduced risk of myocardial infarction (MI) by 13% and fatal MI by 35%.
  • 30,000 coronary heart disease (CHD) patients demonstrated reductions in all-cause mortality (10%), CV mortality (18%), MI (23%), sudden cardiac death (33%), and HF-related hospitalization (25%).

“This new study by Jawad and colleagues provides powerful evidence that omega-3 fatty acids are protective against the development of heart failure, which is one of the most common causes of hospitalization in the US today,” said William S. Harris, PhD, senior investigator of the study and President of the Fatty Acid Research Institute (FARI).

Omega-3 for healthy aging

A pilot study conducted by the University of South Florida highlights the potential benefits of EPAX 4020TGN, a concentrated, marine-derived Omega-3 triglyceride oil from Epax. The research, which included pre-clinical in vivo and in vitro analyses, examined the effects of EPAX 4020TGN on muscle contractile function, post-injury muscle recovery, and cell membrane repair.

Key findings:

  • In an eight-week dietary intervention on adult and aging rats, EPAX 4020TGN inhibited age-related muscle strength loss and significantly improved muscle strength recovery within seven days after injury.
  • In vitro analysis demonstrated that EPAX 4020TGN improved cell membrane repair following damage, which is crucial for maintaining mobility and addressing injuries from falls, compression, or athletic training.

EPAX 4020TGN, part of Epax’s Omega-3 range, features a 2:1 EPA-to-DHA ratio and is suited for use in dietary supplements targeting healthy aging and sports recovery.

“These findings describe a novel means by which EPA and DHA supplementation can support muscle cell repair after injury, and help reduce the muscle decline that occurs as a result of aging," said Dr. Derek Tobin, Clinical Research Manager at Epax. "Additionally, in a sports nutrition context, they demonstrate the potential benefits of Omega-3 for the improvement of muscle recovery after hard training.”

Valerian for sleep

OmniActive Health Technologies shared new data on Sleeproot, a proprietary low-dose valerian extract. Published in Advances in Complementary & Alternative Medicine, the findings reveal that Sleeproot supports a statistically significant increase in sleep duration from the first day of use, alongside reductions in sleep latency (time to fall asleep) and improvements in overall sleep quality throughout supplementation.

Study highlights:

  • Day-One Results: Sleeproot improves sleep duration as early as the first day.
  • Within Three Days: Demonstrates reductions in sleep latency, building on its benefits over time.
  • Eight-Week Study: A prior study published in Advances in Therapy showed improvements in sleep efficiency and occasional anxiety over an extended period.

Sleeproot is a 2% valerian root extract offering a natural alternative to melatonin-based sleep aids. Its green solvent extraction process enhances efficacy at a low dose, the company says, overcoming the typical taste and aroma challenges associated with valerian. Sleeproot is suitable for diverse applications, including capsules, gummies, and ready-to-mix powders.

“We are thrilled to present these advancements, which highlight Sleeproot’s benefits for overall sleep quality,” said OmniActive's VP of Marketing,  Kratika Gupta. “The results reflect a unique, plant-based approach to sleep support, offering consumers an effective, natural alternative sleep aid.”